The bill amends Section 33-32-221 of the Montana Code Annotated to prohibit health insurance issuers from performing prior authorization on certain psychiatric drugs. Specifically, it adds a provision that prevents prior authorization for any prescription drug, whether generic or brand name, that is designated as being in shortage. Additionally, the bill clarifies that the list of psychiatric drugs in shortage will be determined quarterly based on the official shortage list published by the United States Food and Drug Administration.

Furthermore, the bill includes a new provision that prohibits manufacturers of prescription drugs subject to the shortage designation from engaging in predatory pricing or marketing practices related to the shortage. Violations of this provision would be subject to enforcement and penalties as outlined in Title 30, chapter 14, part 1 of the Montana Code. Overall, the bill aims to ensure that patients have better access to necessary psychiatric medications during times of shortage.

Statutes affected:
LC Text: 33-32-221
SB0317_1(1): 33-32-221
SB0317_1(2): 33-32-221
SB0317_1(3): 33-32-221
SB0317_1(4): 33-32-221
SB0317_1(5): 33-32-221
SB0317_1: 33-32-221
SB0317_2(1): 33-32-221
SB0317_2(10): 33-32-221
SB0317_2(2): 33-32-221
SB0317_2(3): 33-32-221
SB0317_2(4): 33-32-221
SB0317_2(5): 33-32-221
SB0317_2(6): 33-32-221
SB0317_2(7): 33-32-221
SB0317_2(8): 33-32-221
SB0317_2(9): 33-32-221
SB0317_2: 33-32-221
SB0317_X(1): 33-32-221
SB0317_X(2): 33-32-221
SB0317_X: 33-32-221